Glucagon-like peptide-1 (GLP-1) compounds have emerged as a compelling therapeutic target for managing metabolic conditions. These naturally occurring hormones are secreted by the gut in response to meal intake, stimulating insulin release and suppressing glucagon release. GLP-1 derivatives demonstrate promising therapeutic results in treating type